bamlanivimab/etesevimab - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.05 [0.00, 0.84]< 10%1 study (1/-)98.0 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.27 [0.14, 0.52]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatecrucial-
viral clearance 1.65 [0.91, 3.00]> 10%1 study (1/-)95.0 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.31 [0.61, 2.83]> 10%1 study (1/-)75.6 %some concernnot evaluable moderateimportant-

safety endpoints 00

emergent treatment-resistant variants 0.18 [0.02, 1.51]< 10%1 study (1/-)94.2 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.